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Background: There is no consensus in the literature regarding the effectiveness of lifestyle modification
interventions, including recommendations about specific diet or exercise program for patients with breast cancer.
Diet interventions and regular physical activity may reduce the risk of breast cancer and its recurrence. The primary
aim of our study is to evaluate the effects of different lifestyle modification interventions (diet and physical activity)
in the survival of patients with stages I to III breast cancer after treatment.
Methods/design: This review will be conducted according to the Cochrane Handbook for Systematic Reviews of
Intervention and will be reported following the PRISMA statement recommendations. CENTRAL, MEDLINE and
EMBASE databases will be searched for peer-reviewed literature. Randomized controlled trials of diet, exercise, or
both, compared with usual care, after treatment of breast cancer stage I to III will be included in the systematic
review. Two authors will independently screen titles and abstracts of studies for potential eligibility. Data will be
combined using random-effect meta-analysis models with restricted maximum-likelihood as variance estimator, and
will be presented as relative risk or standardized mean difference with 95% CI. The quality of evidence will be
assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework
and summary of findings tables will be presented for patient important outcomes.
Discussion: Our study may improve the current understanding of the role that lifestyle-modifiable factors can play
in saving or prolonging the lives of women who have been treated for breast cancer, and also on modifying their
quality of life.
Systematic review registration: The review has been registered with PROSPERO (registration number
CRD42014008743).
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High body mass index (BMI) is well established as a risk
factor for the development of breast cancer, especially
for post-menopausal women [1,2]. More than half of
women diagnosed with breast cancer experience an in-
crease in body weight associated with chemotherapy and
treatment-related menopause [3]. Additionally, there is
evidence that overweight or obese women and women* Correspondence: daniela.rosa@hmv.org.br
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unless otherwise stated.with weight gain after diagnosis have an increased risk
of disease recurrence and death compared to eutrophic
women [4-8]. Women with a high body mass index have
double the risk of five-year breast cancer recurrence and
a 60% increased risk of death over 10 years in compari-
son to women with a normal BMI [6].
Dietary energy restriction reduces body weight, promot-
ing a positive effect on psychological wellbeing in obese
women and breast cancer survivors [9-11]. Weight loss
interventions that reduce the dietary intake of fat to
between 18 and 25% of total calories can also evoke a sig-
nificant reduction in serum estrogen levels in pre- and
post-menopausal women [12]. A diet rich in vegetables andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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in total fat may increase the risk [13]. However, evidence of
an association between a diet high in vegetables and fruit
and low in total fat, and prevention of cancer progression
has been conflicting in epidemiological studies [8,14-21].
Regular physical activity can help to control body weight
and is known to reduce the risk of breast cancer [22-25].
Additional studies also suggest that it can halve the risk of
death in breast cancer patients [26,27]. Regular physical ac-
tivity can also have a positive effect on psychological health
status and quality of life in breast cancer survivors that
could enhance immune function through the normalization
of stress hormone levels [28-30].
There is no consensus in the literature regarding the ef-
fectiveness of lifestyle modification interventions, includ-
ing recommendations about a specific diet or exercise
program for patients with breast cancer. The results of ob-
servational studies evaluating lifestyle modification and
breast cancer recurrence have been mixed. In addition,
the randomized clinical trials that have been published are
inconclusive [31,32] and there are no recent systematic
reviews assessing this topic. Therefore, the primary aim of
our study is to evaluate the effects of different lifestyle
modification interventions (diet and physical activity) in
the survival and disease-free survival of patients with
stages I to III breast cancer after treatment.
Methods/design
We will conduct this review according to the Cochrane
Handbook for Systematic Reviews of Intervention [33] and
we will report data following the PRISMA statement rec-
ommendations [34].We will assess the quality of evidence
for each outcome according to Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE)
framework [35,36]. The review has been registered with
PROSPERO (registration number: CRD42014008743).
Inclusion criteria
The type of studies included will be randomized con-
trolled trials of diet, exercise, or both, compared to usual
care, after treatment of breast cancer stage I to III. The
participants to be included will be women with invasive
breast cancer, stage I to III, who were treated with curative
intent in the previous five years, with no evidence of dis-
ease recurrence. The types of interventions considered will
be as follows: (1) dietary advice delivered through group
meetings, by telephone calls, or by mail correspondence;
(2) individualized dietary counseling; (3) prescription of a
specific diet, such as a calorie-restricted diet; (4) any type
of exercise counseling that encouraged women to engage
in regular recreational exercises, such as walking, jogging
or sports; and (5) structured or individualized exercise
programs or interventions in which women participated
in supervised exercise sessions.Types of outcomes
The primary outcomes of the systematic review are over-
all survival and disease-free survival (five years post
treatment and at the study maximum follow-up period
for both outcomes).
We will also evaluate the following secondary outcomes:
(1) diet and exercise related modifiable risk factors
(weight, BMI, waist-hip ratio and body fat); (2) mediators
and other metabolic factors potentially associated with
breast cancer (adiponectin, leptin, IGF-1, IGFBP1,
IGFBP2, insulin, C-peptide, HOMA-IR, estradiol, tes-
tosterone and SHBG); (3) quality of life; and (4) adverse
events (such as exercise-induced injuries or side effects
of very low-calorie diets).
Search strategy and sources
The following electronic databases will be searched for
peer-reviewed literature: Cochrane Database of System-
atic Reviews, Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, and EMBASE. The
search strategy was developed based on search strategies
from published filters and systematic reviews [37-39],
and is detailed in Additional file 1.
In addition, we will perform an electronic search for on-
going studies at ClinicalTrials.gov and hand searches of
reference lists of included articles and of the proceedings
of the following major conferences: American Society of
Clinical Oncology (2010 to 2014), San Antonio Breast
Cancer Symposium (2010 to 2014), European Society of
Medical Oncology (2010 to 2014), Society for Integrative
Oncology (2010 to 2014), American Association for Cancer
Research (AACR) (2010 to 2014), and World Cancer Re-
search Fund International (2010 to 2014).
Data collection and analysis
Study selection
Two authors will independently screen titles and abstracts
of studies for potential eligibility. Full texts of potentially
eligible studies will be retrieved and two authors will in-
dependently apply inclusion criteria to identify relevant
studies to be included in the review. Disagreement will
be resolved through discussion; if necessary, a third re-
viewer will be involved. We will provide a table with
characteristics of included studies, and another table of
excluded studies with reasons for their exclusion, in the
final review.
Data extraction and management
Two reviewers will independently extract data using a
standardized form. The following data will be abstracted:
(1) characteristics of trial participants (age, ethnicity,
BMI, weight, body fat, waist-hip ratio, breast cancer
stage, treatment, and breast cancer biological subtype);
(2) type of intervention (such as type of diet or exercise
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cording to individual studies; and (4) methodological
quality of individual studies, according to the Cochrane
Handbook for Systematic Reviews [33].
Disagreement will be resolved through discussion. When
quantitative data is not reported, approximate values will be
estimate from the figures or calculated from proportions.
Quality assessment
The risk of bias of all eligible studies will be assessed
independently by two reviewers using the Cochrane
Collaboration’s Risk of Bias tool [33]. Disagreement will
be resolved through discussion. Overall quality of evi-
dence will be assessed using GRADE by a GRADE
working group member and will checked by a second
reviewer [35,36].
Data synthesis and presentation
Data will be combined using random-effect meta-analysis
models, with restricted maximum-likelihood (REML) vari-
ance estimator and presented as relative risks (RR) or
standardized mean difference (SMD) with 95% confidence
intervals (CI). All analyses will be performed using the
R software, version 3.0.2 (R: A Language and Environment
for Statistical Computing, Vienna, Austria); packages
‘meta’ version 3.0-1 (meta: Meta-Analysis with R. R
package version) and ‘metafor’ version 1.9-1 (Conducting
meta-analyses in R with the metafor package) [40,41].
GRADE summary of findings tables will be presented for
the primary outcomes [42,43].
Heterogeneity
We will assess statistical heterogeneity in each meta-
analysis using the I2 statistics. We will regard heterogeneity
as substantial if the I2 is greater than 50%. Heterogeneity
will be explored through pre-specified subgroup and sensi-
tivity analysis as presented below.
Publication bias
If there are 10 or more studies in the meta-analysis we
will investigate publication bias using funnel plots and
Egger`s test [44]. If asymmetry is suggested by a visual
assessment, we will perform exploratory analyses to in-
vestigate and adjust it (trim and fill analysis) [45].
Missing data
For included studies, we will note levels of attrition. We
will explore the impact of including studies with high
levels of missing data in the overall assessment of treat-
ment effect by using sensitivity analysis.
For all outcomes, we will carry out analyses, as far as
possible, on an intention-to-treat basis, in that we will
attempt to include all participants randomized to each
group in the analyses, and all participants will be analyzedin the group to which they were allocated, regardless of
whether or not they received the allocated intervention.
The denominator for each outcome in each trial will be
the number randomized minus the number of participants
whose outcomes are known to be missing.Sensitivity analysis
In order to identify potential sources of heterogeneity,
we will perform the following subgroup analysis: (1) type
of intervention (diet, exercise, or both); (2) breast cancer
treatment (adjuvant versus neoadjuvant); (3) tumor stage
(according to AJCC) [46]; (4) subtypes of breast cancer
according to immunohistochemistry (positivity for HR
and/or HER2); (5) Mean follow-up period (≥24 months)
and (6) risk of bias of included studies). Additionally,
meta-regression will be performed according to the
mean follow-up period of the included studies.Discussion
The results of this study may improve our understanding
of the role that lifestyle-modifiable factors can play in
saving or prolonging the lives of women who have been
treated for breast cancer, and also on modifying their
quality of life. Additionally, this study will provide evi-
dence that may be used for the development of recom-
mendations in guidelines of breast cancer treatment.Additional file
Additional file 1: Search strategy for electronic databases. Search
strategy developed for CENTRAL, MEDLINE (OVID) and EMBASE (OVID).
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